Aura Biosciences

Aura Biosciences
Name	Aura Biosciences
Industry	Biotechnology
Founded	2009
Founder	Elisabet de los Pinos
Location	Cambridge, Massachusetts, United States
Key people	Elisabet de los Pinos (CEO), Cadmus Rich (CFO)
Products	Belzupacap sarotalocan (AU-011)
Website	aurabiosciences.com

Aura Biosciences is a clinical-stage biotechnology company pioneering novel targeted therapies for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts and is focused on developing its lead candidate, belzupacap sarotalocan, for ocular oncology. Its core technology utilizes virus-like particles conjugated with photosensitizers to selectively target and destroy cancer cells while sparing healthy tissue, a modality known as targeted phototherapy.

Company Overview

Founded in 2009 by Elisabet de los Pinos, Aura Biosciences operates as a publicly traded entity on the NASDAQ under the ticker symbol AURA. The company’s mission centers on addressing significant unmet medical needs in cancers with limited treatment options, particularly within ophthalmology. Its primary research and development efforts are concentrated on uveal melanoma, a rare and life-threatening form of eye cancer that originates in the choroid of the eye. The company maintains its corporate and research operations in the biotechnology hub of Cambridge, Massachusetts, leveraging the region's dense network of academic and research institutions like Harvard University and the Massachusetts Institute of Technology.

Technology Platform

Aura’s proprietary technology platform is based on virus-like particles derived from the human papillomavirus. These nanoparticles are engineered to be non-infectious and are conjugated with a potent photosensitizer molecule. Upon intravenous administration, these VLP conjugates selectively bind to heparan sulfate proteoglycans, which are overexpressed on the surface of many cancer cells, including those in uveal melanoma. Following binding, the targeted cells are illuminated with a near-infrared laser, activating the photosensitizer. This activation generates reactive singlet oxygen that induces rapid, selective cancer cell death via necrosis while minimizing damage to surrounding critical structures like the retina and optic nerve.

Clinical Development

The company’s lead asset, belzupacap sarotalocan, is currently in Phase 2 clinical development for the first-line treatment of indeterminate lesions and small choroidal melanoma. Early-stage trials, including a Phase 1b/2 study, have been conducted at leading oncology centers such as the University of California, San Francisco and the Wills Eye Hospital. The clinical program aims to demonstrate the therapy’s potential to preserve vision and avoid the severe side effects associated with traditional treatments like plaque radiotherapy and enucleation. The U.S. Food and Drug Administration has granted Orphan Drug Designation and Fast Track Designation to belzupacap sarotalocan for the treatment of choroidal melanoma.

Strategic Collaborations

To advance its platform and expand its pipeline, Aura Biosciences has entered into key strategic partnerships. A significant collaboration exists with LensAR Laser System, part of the Carl Zeiss Meditec AG group, to develop a combined laser system for the precise delivery of its therapy. The company has also engaged in research agreements with institutions like the Massachusetts Eye and Ear Infirmary to further explore the biology of ocular cancers. These alliances are designed to accelerate clinical development and facilitate the potential commercialization of its therapeutic platform.

Financial Information

As a development-stage company, Aura Biosciences has financed its operations through both private investment and public market offerings. Following its initial public offering, the company’s financial resources are allocated primarily toward research and development activities, clinical trial execution, and general corporate purposes. Key financial milestones and operational updates are regularly disclosed through filings with the U.S. Securities and Exchange Commission. The company’s investor base includes several prominent venture capital firms and institutional investors from the biotechnology sector.

Leadership and Governance

The company is led by its founder and Chief Executive Officer, Elisabet de los Pinos, who has a background in venture capital and drug development. Other key members of the executive team include Chief Financial Officer Cadmus Rich and Chief Medical Officer Dr. Mark I. Greene. The board of directors includes experienced leaders from the pharmaceutical and biotechnology industries, providing strategic oversight. This governance structure is designed to guide the company through late-stage clinical development and toward potential regulatory submissions to agencies like the U.S. Food and Drug Administration and the European Medicines Agency.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Medical and health organizations based in Massachusetts